UCB (STU:UNC) Other Financing: €-128 Mil (TTM As of Dec. 2025)


STU:UNC UCB SA STU:UNC
89 GF Score
Price €250.00
GF Value €211.18
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is UCB Other Financing?

UCB STU:UNC -1.46% 89 Other Financing is €-128 Mil as of Dec. 2025. GuruFocus rates STU:UNC with a GF Score™ of 89/100 and a GF Value™ of €211.18 (Modestly Overvalued). The stock has 2 warning signs investors should review.

UCB's Other Financing for the six months ended in Dec. 2025 was €-56 Mil.

UCB's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was €-128 Mil.

UCB Other Financing Historical Data

* Premium members only.

The historical data trend for UCB's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB Other Financing Chart

UCB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -63.00 -74.00 -144.00 -160.00 -128.00

UCB Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.00 -121.00 -39.00 -72.00 -56.00
STU:UNC
89GF Score
UCB SA STU:UNC
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UCB Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-128 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €-128 Mil mean?
UCB (STU:UNC) has a Other Financing of €-128 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for UCB and its competitors.
Is UCB's Other Financing too high?
UCB's current Other Financing is €-128 Mil. Overall, UCB has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UCB's Other Financing compare to VRTX and REGN?
UCB's Other Financing of €-128 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for UCB and its competitors. UCB's current Other Financing is €-128 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Overvalued. The stock's GF Value™ is €211.18, compared to a current price of €250.00 — trading 18.4% above its estimated fair value. The current Other Financing is €-128 Mil. UCB's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For UCB (STU:UNC), the current Other Financing is €-128 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UCB (STU:UNC) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be overvalued. The current stock price of €250.00 is trading 18.4% above its estimated GF Value™ of €211.18. GuruFocus considers UCB to be Modestly Overvalued.

Key valuation signals for STU:UNC:

  • Other Financing: €-128 Mil
  • GF Value™: €211.18 vs. price of €250.00 (18.4% above fair value)
  • GF Score™: 89/100 with 2 warning signs

No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
89GF Score

Get the complete analysis for STU:UNC

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€250.00
Price
€211.18
GF Value